Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14058531 | 0.84 | GAA (0.57) | GAAALDH1A1CYP1A2RECQLCYP2C9 | |
| SCHEMBL4104400 | 0.82 | GAA (0.62) | GAAALDH1A1CYP1A2RECQLCYP2C9 | |
| SCHEMBL31208305 | 0.82 | GAA (0.62) | GAAALDH1A1CYP1A2RECQLCYP2C9 | |
| SCHEMBL10601228 | 0.81 | MAOB (0.62) | GAAALDH1A1SMN1; SMN2MAOB | |
| SCHEMBL2452322 | 0.80 | GAA (0.69) | GAAALDH1A1CYP1A2RECQLCYP2C9 | |
| SCHEMBL20125239 | 0.80 | GAA (0.59) | GAAALDH1A1CYP1A2RECQLCYP2C9 | |
| SCHEMBL4917285 | 0.79 | GAA (0.54) | GAAALDH1A1CYP1A2RECQLCYP2C9 | |
| SCHEMBL17354801 | 0.78 | MAOB (0.49) | ALDH1A1MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL17770699 | 0.77 | GAA (0.65) | GAAALDH1A1CYP1A2RECQLCYP2C9 | |
| SCHEMBL4853171 | 0.77 | GAA (0.65) | GAAALDH1A1CYP1A2RECQLCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302516-A1 | NANOPARTICLES FOR DRUG DELIVERY | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| EP-2490723-A1 | NANOPARTICLES FOR DRUG DELIVERY | University Of Louisville Research Foundation, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011049972-A1 | NANOPARTICLES FOR DRUG DELIVERY | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302516-A1 | NANOPARTICLES FOR DRUG DELIVERY | HIF1AN, CD47, EGLN2 | GAA 2209/4885ALDH1A1 757/4885CYP1A2 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.